The new $35 copay cap, effective April 7, covers most of Eli Lilly’s insulins, including its Humalog injection.
Uninsured patients and those with commercial insurance are eligible to receive the discounted rate. However, Medicare and Medicaid patients are not eligible due to federal guidelines, the drugmaker said.
“Too many people in the U.S. have lost their jobs because of the COVID-19 crisis, and we want to make sure no one goes without their Lilly insulin,” said Mike Mason, president of Lilly Diabetes. “We’ve been providing affordability solutions for a long time, but more is needed to help people during this unprecedented period.”
Read the full news release here.
More articles on pharmacy:
Gilead boosts remdesivir production, now has 1.5M doses
Walgreens adds 6 COVID-19 safety measures to protect workers
2 East Coast pharmacy schools graduating students early to fight COVID-19
